Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that on October 25, it has established its European regional headquarters, "Eisai Europe Limited", in the U.K.
Establishment of Eisai Europe Limited will enhance Eisai's further business expansion into the new European markets and strengthen its consolidated management through rapid decision-making and efficient utilization of capital. As the integration and expansion of Europe proceeds, the company will maximize business opportunities in Europe and increase profitability.
In the future, Eisai Europe Limited will function as the holding company of the current subsidiaries including Eisai Ltd. (the U.K.), Eisai GmbH (Germany), Eisai S.A.S. (France), Eisai Farmaceutica S.A. (Spain), Eisai B.V. (the Netherlands), and Eisai London Research Laboratories, Ltd., and perform the same function for new companies to be established.
Currently, Eisai's European operations are concentrated on marketing ARICEPT
, an Alzheimer's disease treatment, and Pariet
, a proton pump inhibitor, in the U.K., Germany, France and Spain. Eisai continues to strive to introduce new products into existing and new markets to fulfill unmet medical needs.